Why CRISPR Therapeutics Stock Rocked the Market Last Month
The company had fallen out of investor favor; its recovery was impressive.
Overview
Pioneering gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) was a well-performing biotech stock in August. Its shares were hot in the hot month, zooming almost 19% higher thanks to a solid quarterly earnings report and business update.
CRISPR released its second-quarter financials and business update early in the month, on Aug. 3, to be exact. It quoted CEO Samarth Kulkarni as saying that this "reflected strong execution across CRISPR Therapeutics' portfolio and platform" -- and he was not wrong.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.